Uncategorized

If approved, CSX-1004 would be the first FDA-approved therapy for prevention of fentanyl-related overdose– CHAPEL HILL, N.C.–(BUSINESS WIRE)–Cessation Therapeutics, Inc. (“Cessation”), a clinical-stage biotechnology company advancing biologics that target substances of abuse, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CSX-1004, an investigational therapy for prevention of fentanyl-related …

Cessation Therapeutics Receives FDA Fast Track Designation for CSX-1004 for Prevention of Fentanyl and Fentanyl Analog Overdose Read More »

CHAPEL HILL, N.C.–(BUSINESS WIRE)–Cessation Therapeutics, Inc. (“Cessation), a clinical-stage biotechnology company advancing biologics that target substances of abuse, today announced that it has been awarded an additional grant from the National Institute on Drug Abuse (NIDA, a division of the National Institutes of Health) to support development of a subcutaneous formulation of its anti-fentanyl mAb, …

Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel Formulation of Anti-Fentanyl Monoclonal Antibody Read More »

CHAPEL HILL, N.C.–(BUSINESS WIRE)–Cessation Therapeutics, Inc., (“Cessation”) a clinical-stage biotechnology company advancing biologics that target substances of abuse, announced today that the U.S. Food and Drug Administration (FDA) has authorized the company to initiate a clinical trial in the U.S. for CSX-1004, a monoclonal antibody designed specifically to prevent fentanyl overdose.

As a Navy admiral, I helped lead one of the most powerful militaries in the world. Today, our nation is fighting an urgent war right here at home. The opioid crisis in America has now become a fentanyl crisis. A synthetic opioid that is at least 50 times more potent than morphine, fentanyl is both exceedingly …

Tens of Thousands of Americans are Dying Every Year from Fentanyl Overdose It’s time to fight fentanyl like the foe that it is Read More »

CHAPEL HILL, N.C.–(BUSINESS WIRE)–Cessation Therapeutics (“Cessation”), an early-stage biotechnology company focused on the development of novel immunobiologics for preventing and treating fentanyl overdose, today announced a new study demonstrating that its pioneering anti-fentanyl monoclonal antibody treatment, CSX-1004, may provide robust and durable protection from life-threatening respiratory depression caused by high doses of fentanyl.